CRIS Current Research Information System

CASTELLUCCI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.394
AS - Asia 6.809
EU - Europa 6.495
AF - Africa 567
SA - Sud America 397
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 23.670
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.299
SG - Singapore 2.095
CN - Cina 1.891
GB - Regno Unito 1.765
VN - Vietnam 1.501
DE - Germania 942
SE - Svezia 857
IT - Italia 846
HK - Hong Kong 505
RU - Federazione Russa 390
IN - India 366
UA - Ucraina 323
FR - Francia 298
BR - Brasile 285
IE - Irlanda 276
FI - Finlandia 154
TG - Togo 154
NL - Olanda 145
CI - Costa d'Avorio 140
ZA - Sudafrica 137
EE - Estonia 122
KR - Corea 112
CH - Svizzera 107
JO - Giordania 100
BG - Bulgaria 81
JP - Giappone 81
CA - Canada 74
SC - Seychelles 69
AR - Argentina 57
NG - Nigeria 47
BE - Belgio 37
ID - Indonesia 33
IR - Iran 32
AT - Austria 31
PL - Polonia 28
ES - Italia 27
BD - Bangladesh 18
EC - Ecuador 18
MX - Messico 16
TR - Turchia 13
HR - Croazia 12
CZ - Repubblica Ceca 9
CL - Cile 8
IQ - Iraq 8
LT - Lituania 8
GR - Grecia 7
PE - Perù 7
PY - Paraguay 7
RO - Romania 7
UZ - Uzbekistan 7
CO - Colombia 6
LB - Libano 6
SK - Slovacchia (Repubblica Slovacca) 6
MA - Marocco 5
MY - Malesia 5
TN - Tunisia 5
AU - Australia 4
HU - Ungheria 4
KZ - Kazakistan 4
PK - Pakistan 4
PT - Portogallo 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BJ - Benin 3
SA - Arabia Saudita 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
EG - Egitto 2
KE - Kenya 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MN - Mongolia 2
NO - Norvegia 2
PH - Filippine 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
BN - Brunei Darussalam 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
FK - Isole Falkland (Malvinas) 1
HN - Honduras 1
IL - Israele 1
KW - Kuwait 1
MD - Moldavia 1
MT - Malta 1
MU - Mauritius 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
RE - Reunion 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 23.670
Salva come PNG Salva come JPEG
Città #
Southend 1.575
Singapore 1.413
Ashburn 1.173
Fairfield 934
Chandler 899
Hong Kong 504
Wilmington 450
Houston 449
Woodbridge 430
Seattle 413
Santa Clara 402
Cambridge 344
Princeton 341
Beijing 290
Ann Arbor 279
Dublin 275
Hefei 251
Dong Ket 234
Boardman 224
Jacksonville 214
Lomé 154
Westminster 149
Bologna 147
Los Angeles 146
Abidjan 140
Helsinki 138
Padova 131
Nanjing 127
Ho Chi Minh City 125
Munich 121
New York 119
Berlin 110
Seoul 110
Hanoi 106
Amman 100
Bern 100
Jinan 83
Dallas 76
Tokyo 76
Shenyang 74
Sofia 74
Saint Petersburg 71
Turin 67
Buffalo 63
Florence 62
Redondo Beach 60
Milan 58
Changsha 56
Hebei 52
Bremen 48
Frankfurt am Main 47
Mülheim 47
Abeokuta 44
Redmond 44
San Diego 44
Tianjin 44
Guangzhou 42
Nanchang 41
Medford 38
Jiaxing 37
Shanghai 37
Brussels 36
São Paulo 35
Redwood City 34
Zhengzhou 32
Toronto 31
Nuremberg 27
Falkenstein 26
Phoenix 26
Chicago 25
Dearborn 25
Bengaluru 24
Des Moines 24
London 24
Norwalk 24
Yubileyny 22
Mahé 21
Tongling 21
Brooklyn 20
Hangzhou 20
Haikou 18
Kuban 18
Taiyuan 18
Falls Church 17
Jakarta 17
Orem 17
Taizhou 17
Wuhan 17
Da Nang 16
Johannesburg 16
Ottawa 16
Ningbo 15
Olalla 15
Amsterdam 14
Kunming 14
Warsaw 14
Lauterbourg 13
Vienna 13
Haiphong 12
Montreal 12
Totale 15.308
Salva come PNG Salva come JPEG
Nome #
Combined (18)F-FDG-PET/CT Imaging in Radiotherapy Target Delineation for Head-and-Neck Cancer. 414
18F-FDG PET early after radiotherapy in lymphoma patients. 292
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 283
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study 270
11-C-choline PET/CT imaging for localization of recurrent prostate cancer 263
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 246
11 C-CHOLINE-PET/CT FOR PREOPERATIVE N-STAGING IN HIGH RISK PROSTATE CANCER 230
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 226
11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. 211
Molecular modelling evaluation of exon 18 His845_Asn848delinsPro pDGFRα mutation in a metastatic GIST patient responding to imatinib 209
11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. 208
Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. 198
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 194
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 193
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 192
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. 190
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. 187
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 187
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study 186
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 186
11C-CHOLINE PET/TC imaging for localization of recurrent prostate cancer 185
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 184
18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin 182
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 182
Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). 182
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 181
11C-Choline PET/CT for Restaging of Bladder Cancer 181
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 178
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 178
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. 177
Identification of PET/CT radiomic signature for classification of locally recurrent rectal cancer: A network-based feature selection approach 175
A case of [68Ga]Ga-FAPI-46-avid and [18F]F-FDG-negative COVID-19 pneumonia sequelae 174
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 171
Pathological and molecular diagnosis of bilateral inguinal lymph nodes metastases from low-grade endometrial adenocarcinoma: a case report with review of the literature 170
18 FDG-PET nel follow.up dei pazienti con carcinoma tiroideo differenziato 169
CT with 11C-Choline for identification of recurrent prostate cancer 168
Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. 168
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 168
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 168
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study 166
18f-fdg pet/ct for restaging gastric cancer after surgical resection 165
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. 164
Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer 164
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 163
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 162
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 162
PET-TC con 11C-colina e Spettroscopia di Risonanza Magnetica nella diagnosi e localizzazione del tumore prostatico: confronto con l'analisi seriata dello specimen chirurgico. 162
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 161
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 160
CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report 158
EFFETTO DELLA TERAPIA ORMONALE SULLA CAPTAZIONE DI 11-C-COLINA IN PAZIENTI CON RIPRESA DI MALATTIA DA CARCINOMA PROSTATICO 158
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 156
Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. 154
11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. 154
Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection 153
Evaluation of unusual neuroendocrine tumours by means of (68)Ga-DOTA-NOC PET. 153
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 153
Image fusione between PET and CT for radiotherapy treatment planning for head and neck cancer 151
Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study 151
11C-methionine vs. 18F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: preliminary results 150
TOMOGRAFIA AD EMISSIONE DI POSITRONI CON 11-C-COLINA INTEGRATO A UN SISTEMA TC (11-C-CHOLINE-PET/TC) E RISONANZA MAGNETICA DI SPETTROSCOPIA DEL PROTONE (1-H-MRSI) NELLA DIAGNOSI DI NEOPLASIA PROSTATICA: STUDIO COMPARATIVO 149
[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy. 148
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 148
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 145
(18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. 145
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 144
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. 144
POSITRON-EMISSION TOMOGRAPHY IN IMAGING AND STAGING PROSTATE CANCER 144
Sextant localization of prostate cancer:comparison between Magnetic Resonance Spectroscopic Imaging and 11C-Choline PET-CT. 143
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 143
Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer. 142
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 141
Pictorial essay: normal variants, lesions, and pitfalls in Ga-68-PSMA PET imaging of prostate cancer. 141
Sextant localization of prostate cancer with 11-C-choline PET/CT: comparison with three-dimensional proton MR spectroscopic imaging using step section histopathology as standard of references 139
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. 139
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 138
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 138
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 136
Incidental finding of an (11)C-choline PET-positive solitary plasmacytoma lesion. 136
Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer 136
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 136
PET/TC CON 11-C-COLINA E SPETTROSCOPIA DO RISONANZA MAGNETICA NELLA DIAGNOSI E LOCALIZZAZIONE DEL TUMORE PROSTATICO: CONFRONTO CON LA ANALISI SERIATA DELLO SPICIMEN CHIRURGICO 135
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 135
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 135
C–CHOLINE PET/CT IMAGING IS USEFUL FOR METASTATIC LYMPH NODES DETECTION IN NEWLY DIAGNOSED PROSTATE CANCER 134
Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis 134
Role of (11)C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy 133
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 133
C–CHOLINE PET/CT IMAGING IS USEFUL FOR METASTATIC LYMPH NODES DETECTION IN NEWLY DIAGNOSED PROSTATE CANCER 132
TOMOGRAFIA AD EMISSIONE DI POSITRONI CON 11-C-COLINA INTEGRATO A UN SISTEMA TC (11-C-CHOLINE-PET/TC) NELLA DIAGNOSI DI NEOPLASIA PROSTATICA 132
Management of patients with gastrointestinal stromal tumor in clinical practice in Italy: a critical "event tree model" analysis of decision-making processes and outcomes. 131
Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL. 131
IL RUOLO DELLA 11C-COLINA PET/CT IN PAZIENTI CON RECIDIVA BIOCHIMICA DOPO PROSTATECTOMIA RADICALE E CARCINOMA PROSTATICO ORMONO-RESISTENTE SOTTOPOSTI A TERAPIA DI DEPRIVAZIONE ANDROGENICA 130
Role of 11C-Choline PET/CT in androgen sensitive prostate cancer patients treated with intermittent ADT: A sequential PET/CT study after therapy interruption 129
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 128
SEXTANT LOCALIZATION OF PROSTATE CANCER WITH 11C-CHOLINE PET/CT: COMPARISON WITH THREE-DIMENSIONAL PROTON MR SPECTROSCOPIC IMAGING USING STEP SECTION HISTOPATHOLOGY AS STANDARD OF REFERENCES 127
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 127
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. 126
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 125
Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? 124
Totale 16.682
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.791
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.443 0 0 0 0 0 116 36 181 279 87 128 616
2021/20223.598 892 89 188 295 286 139 57 193 100 181 701 477
2022/20233.781 361 546 232 477 237 293 98 202 695 128 302 210
2023/20241.129 95 165 31 68 72 220 57 262 50 56 26 27
2024/20253.838 167 561 284 278 666 248 300 132 95 212 157 738
2025/20264.063 650 728 707 565 1.009 404 0 0 0 0 0 0
Totale 24.105